Published in
Oxford University Press, Neuro-Oncology, 7(17), p. 1007-1015, 2015
Links
- ORCID
- Oxford University Press
- ORCID
- [hdl.handle.net]
- [www.zora.uzh.ch] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.zora.uzh.ch] | PDF
- [europepmc.org] | PDF
- [www.zora.uzh.ch] | PDF
Tools
Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma
Journal article published in 2015 by
Ulrik Lassen 
,
Olivier L. Chinot ,
Catherine A. McBain,
Morten Mau-Sorensen,
Vibeke Andrée Larsen,
Maryline Barrie,
Patrick Roth,
Oliver Krieter,
Ka Wang,
Kai Habben,
Jean Tessier,
Angelika Lahr,
Michael Weller
,
Olivier L. Chinot ,
Catherine A. McBain,
Morten Mau-Sorensen,
Vibeke Andrée Larsen,
Maryline Barrie,
Patrick Roth,
Oliver Krieter,
Ka Wang,
Kai Habben,
Jean Tessier,
Angelika Lahr,
Michael Weller
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
We conducted a phase 1 dose-escalation study of RO5323441, a novel antiplacental growth factor (PlGF) monoclonal antibody, to establish the recommended dose for use with bevacizumab and to investigate the pharmacokinetics, pharmacodynamics, safety/tolerability, and preliminary clinical efficacy of the combination.